Emboline, a privately held medical technology company focused on reducing stroke during transcatheter heart procedures, today announced it completed raising over $10 million in Series C funding, from new and existing investors. Funds raised will be used to obtain initial commercial approval of the Emboliner and to launch its upcoming US IDE clinical study, which are both anticipated in 2021.

Emboline is a privately held medical technology company that has developed the Emboliner™ Total Embolic Protection Catheter, the first embolic protection device designed to provide total embolic protection by capturing and removing all debris from transcatheter procedures that would otherwise travel to the brain, kidneys and other critical organs, and reducing the incidence of stroke, cerebral ischemia, cognitive decline and other adverse outcomes associated with procedure-related emboli. Emboline's technologies are derived from intellectual property invented by Amir Belson, MD, founder of NeoGuide Systems, Vascular Pathways, ZipLine Medical, Qool Therapeutics, Radiaction and others. More information is available at www.emboline.com.